Tempus AI, Inc. (TEM) Net Profit Margin: -22.20%
Is Tempus AI, Inc.’s net profit margin high or low?
Tempus AI, Inc.'s net profit margin of -22.20% is 71% above its 5-year average of -77.31%, near the high end of its 5-year range (-111.62%–-19.27%).
As of Friday, June 12, 2026. 63.32% above its 12-month average of -60.53%.
TEM Net Profit Margin Chart
TEM Average Net Profit Margin Chart
TEM Current vs Average Net Profit Margin Chart
TEM Net Profit Margin Metrics
NET PROFIT MARGIN
-22.20%
NET PROFIT MARGIN AVG TTM
-60.53%
NET PROFIT MARGIN AVG 3Y
-62.93%
NET PROFIT MARGIN AVG 5Y
-77.31%
NET PROFIT MARGIN AVG 10Y
-92.72%
NET PROFIT MARGIN AVG 15Y
-92.72%
NET PROFIT MARGIN AVG 20Y
-92.72%
CURRENT VS TTM AVG
+63.32%
CURRENT VS 3Y AVG
+64.72%
CURRENT VS 5Y AVG
+71.28%
CURRENT VS 10Y AVG
+76.06%
CURRENT VS 15Y AVG
+76.06%
CURRENT VS 20Y AVG
+76.06%
TEM Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $8.65B | -22.20% | -60.53% | -62.93% | -77.31% |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | -4.59% | -1.67% | 5.09% | 7.31% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.91B | 6.52% | -21.22% | -48.94% | 16.61% |
| Baxter International Inc. (BAX) | $10.58B | -9.70% | -7.30% | -3.29% | 1.14% |
| Hims & Hers Health, Inc. (HIMS) | $6.44B | -0.56% | 7.00% | -0.29% | -8.82% |
| Align Technology, Inc. (ALGN) | $12.64B | 10.50% | 10.36% | 10.48% | 22.21% |
| Solventum Corporation (SOLV) | $13.72B | 17.33% | 12.25% | 14.36% | 15.15% |
| Hologic, Inc. (HOLX) | $16.97B | 13.18% | 16.70% | 17.87% | 22.37% |
| 23andMe Holding Co. (ME) | $15.31M | -134.54% | -225.74% | -158.88% | -132.14% |
| Moderna, Inc. (MRNA) | $19.70B | -143.55% | -128.24% | -70.25% | -50.87% |
Margin Comparison
Operating Margin
-18.1%
Net Profit Margin
-22.2%
Tempus AI, Inc. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tempus AI, Inc. Net Profit Margin FAQ
- What is the net profit margin for Tempus AI, Inc. (TEM)?
- The net profit margin for TEM stock is -22.20%.
- Is Tempus AI, Inc.'s net profit margin high or low?
- Tempus AI, Inc.'s net profit margin of -22.20% is 71% above its 5-year average of -77.31%, near the high end of its 5-year range (-111.62%–-19.27%).
- What is the TTM average net profit margin for Tempus AI, Inc. (TEM)?
- The TTM average net profit margin for TEM stock is -60.53%.
- What is the 3Y average net profit margin for Tempus AI, Inc. (TEM)?
- The 3Y average net profit margin for TEM stock is -62.93%.
- What is the 5Y average net profit margin for Tempus AI, Inc. (TEM)?
- The 5Y average net profit margin for TEM stock is -77.31%.
- What is the 10Y average net profit margin for Tempus AI, Inc. (TEM)?
- The 10Y average net profit margin for TEM stock is -92.72%.
- What is the 15Y average net profit margin for Tempus AI, Inc. (TEM)?
- The 15Y average net profit margin for TEM stock is -92.72%.
- What is the 20Y average net profit margin for Tempus AI, Inc. (TEM)?
- The 20Y average net profit margin for TEM stock is -92.72%.
Tempus AI, Inc. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | -19.27% |
| 2024-12-31 | -101.79% |
| 2023-12-31 | -40.26% |
| 2022-12-31 | -90.38% |
| 2021-12-31 | -100.52% |
| 2020-12-31 | -111.62% |
| 2019-12-31 | -185.23% |
Related Metrics
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky